Chlorogenic acid (Synonyms: 3OCaffeoylquinic acid, Heriguard, NSC 407296) |
| رقم الكتالوجGN10308 |
حمض الكلوروجينيك هو مركب فينولي رئيسي في القهوة والشاي.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 327-97-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Chlorogenic acid is a potent neuroprotective agent and also has antiviral,antifungal antioxidant and antitumor properties. CGA is also involved in regulating glucose and lipid metabolism and improving insulin sensitivity [1].
Chlorogenic acid (25, 50 μM; 24h) dose-dependently reduced the expression of p-c-Myc and increased the expression of p21 in U87MG and M059J cells[1]; Chlorogenic acid (30, 60 μM, 24h) inhibited the proliferation of B16 melanoma cells; After co-incubation of B16 melanoma cells with 8-methoxypsoralen (8-MOP), chlorogenic acid (500 μM, 24h) reduced melanin production in B16 melanoma cells and inhibited tyrosinase activity[2].
Chlorogenic acid (75mg/kg, ip, bid) inhibited the tumor growth of rat C6 glioma, with a tumor volume inhibition rate of 57%[1]. In the LPS-induced acute lung injury model, chlorogenic acid (50 mg/kg, ip) inhibited the LPS-induced increase in lung tissue MPO activity and the migration of neutrophils (PMN) to bronchoalveolar lavage fluid (BALF), and blocked the release of nitric oxide (NO) induced by LPS stimulation [3]. Chlorogenic acid (100 mg/kg, ip, biw, 6 weeks) treatment inhibited HFD-induced liver steatosis and insulin resistance. Chlorogenic acid inhibited the expression of liver Pparγ, Cd36, Fabp4 and Mgat1 genes, reduced inflammation in the liver and white adipose tissue, and was accompanied by a decrease in the mRNA levels of macrophage marker genes (including F4/80, Cd68, Cd11b, Cd11c, and Tnfα, Mcp-1 and Ccr2 encoding inflammatory proteins) [4].
References:
[1]. Huang S, Wang LL, Xue NN, Li C, Guo HH, Ren TK, Zhan Y, Li WB, Zhang J, Chen XG, Han YX, Zhang JL, Jiang JD. Chlorogenic acid effectively treats cancers through induction of cancer cell differentiation. Theranostics. 2019 Sep 19;9(23):6745-6763.
[2]. Li HR, Habasi M, Xie LZ, Aisa HA. Effect of chlorogenic acid on melanogenesis of B16 melanoma cells. Molecules. 2014 Aug 25;19(9):12940-8.
[3]. Zhang X, Huang H, Yang T, Ye Y, Shan J, Yin Z, Luo L. Chlorogenic acid protects mice against lipopolysaccharide-induced acute lung injury. Injury. 2010 Jul;41(7):746-52.
[4]. Ma Y, Gao M, Liu D. Chlorogenic acid improves high fat diet-induced hepatic steatosis and insulin resistance in mice. Pharm Res. 2015 Apr;32(4):1200-9.
| Cell experiment [1]: | |
Cell lines | U87MG and M059J cells |
Preparation Method | Chlorogenic acid ( 25 µM, 50 µM ) were treated with U87MG and M059J cells for 24 hours. |
Reaction Conditions | Chlorogenic acid (25,50) μM ;24h |
Applications | Chlorogenic acid dose-dependently decreased p-c-Myc expression and increased p21 expression in cell lines confirming the differentiation-inducing effect of Chlorogenic acid in solid tumors. |
| Animal experiment [1]: | |
Animal models | Xenograft tumor model |
Preparation Method | The animals received an intraperitoneal (ip) injection of Chlorogenic acid (directly dissolved in saline; 25, or 50, or 200 mg/kg/d) for 30 days, and the same volume of saline was used as a control. |
Dosage form | Chlorogenic acid ( 25,50 and 200mg/kg, ip),30 days |
Applications | Chlorogenic acid treatment with ip administration of 25 mg/kg/d, 50 mg/kg/d, or 200 mg/kg/d slowed down the growth of the tumor mass, yielding 44.0%, 80.1% or 83.1% tumor volume inhibition of Huh7 tumors and 39.9%, 84.6%, or 86.3% tumor reduction of H446 tumors, respectively |
References: [1]. Huang S, Wang LL, Xue NN, Li C, Guo HH, Ren TK, Zhan Y, Li WB, Zhang J, Chen XG, Han YX, Zhang JL, Jiang JD. Chlorogenic acid effectively treats cancers through induction of cancer cell differentiation. Theranostics. 2019 Sep 19;9(23):6745-6763. | |
| Cas No. | 327-97-9 | SDF | |
| المرادفات | 3OCaffeoylquinic acid, Heriguard, NSC 407296 | ||
| Chemical Name | (1S,3R,4R,5R)-3-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid | ||
| Canonical SMILES | C1C(C(C(CC1(C(=O)O)O)OC(=O)C=CC2=CC(=C(C=C2)O)O)O)O | ||
| Formula | C16H18O9 | M.Wt | 354.31 |
| الذوبان | ≥ 13.8mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.8224 mL | 14.1119 mL | 28.2239 mL |
| 5 mM | 0.5645 mL | 2.8224 mL | 5.6448 mL |
| 10 mM | 0.2822 mL | 1.4112 mL | 2.8224 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *